POAI - Predictive Oncology Cancer Research Horizons team up to develop cancer drugs

2023-03-17 07:29:21 ET

• Predictive Oncology ( NASDAQ: POAI ) is collaborating with Cancer Research Horizons (CRH) to develop cancer drugs.
• CRH is the innovation arm of Cancer Research UK –  one of the world's largest charitable funders of cancer research, Predictive noted.
• The partnership will use Predictive's PEDAL technology to evaluate Cancer Research Horizons' pre-clinical drug inhibitors of Glutaminase to check which cancer types and patient populations are most likely to respond to treatment with these compounds.
• Predictive said that PEDAL is an artificial intelligence (AI) and machine learning platform which makes drug response predictions to help with an informed selection of drug-tumor type combinations for clinical development.
• "We look forward to applying Predictive Oncology’s expertise, enabling technology and dedication to progress exciting cancer therapeutics," said Tony Hickson, chief business officer for Cancer Research UK and CRH.
• POAI +0.80% to $0.34 premarket March 17

For further details see: